Presentations on the Mechanism of Action of VEGFb™, the World’s only “Angiogenesis Modulator,” Support VEGFb’s Role as a Promising Treatment for Solid Cancers, Macular Degeneration, and Other Diseases
PhiloGene, Inc. Announces that VEGFbTM has been Granted Orphan Drug Designation by the FDA for the Treatment of Advanced Melanoma
see our technology and pipeline

PhiloGene Inc. is a biopharmaceutical company focused on developing and commercializing novel protein therapeutics for unmet medical and patient needs. PhiloGene' in-depth knowledge of protein therapeutics has resulted in a unique approaches that exploit the therapeutic potential of native growth and differentiation factors. As a company, we are committed to improving the quality of life of patients.